Skip to main content
Fig. 5 | Stem Cell Research & Therapy

Fig. 5

From: Enhanced cell survival and therapeutic benefits of IL-10-expressing multipotent mesenchymal stromal cells for muscular dystrophy

Fig. 5

Improved locomotor activity in CXMDJ treated with IL-10-expressing MSCs. a Day-time behavioral activity of normal (left graph), untreated CXMDJ (control DMD), hDPSC-treated CXMDJ (hDPSC-DMD), and IL-10-hDPSC-treated CXMDJ (IL-10-hDPSC-DMD) in home cage at 3, 6, and 12 months presented as mean count activity (average of value for 5 days). Statistical differences between control DMD vs. hDPSC-DMD or IL-10-hDPSC-DMD dog groups (#P < 0.05, ##P < 0.01, ###P < 0.001, ####P < 0.0001) are indicated; ns, not significant, two-way ANOVA. b 15-m running speed of normal, control DMD, hDPSC-DMD, and IL-10-hDPSC-DMD dogs at 12 months. The mean value was the average value of four measurements from each group. Statistical differences between normal vs. DMD (*P < 0.05, **P < 0.01, and ****P < 0.0001), control DMD vs. hDPSC-DMD, or IL-10-hDPSC-DMD (#P < 0.05, ##P < 0.01, ###P < 0.001) are indicated; ns, not significant, one-way ANOVA. Serum creatine kinase (CK) levels c and serum lactic acid levels d in each group before, 0, and 20 min after running exercise, which were four times greater than those after 15-m running, as measured using ELISA. Statistical differences between normal vs. DMD (*P < 0.05, **P < 0.01), control DMD vs. IL-10-hDPSC-DMD (#P < 0.05) are indicated; two-way ANOVA. n = 4 for each group. Data are presented as the mean ± SD

Back to article page